VTL - Vital Therapies, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Vital Therapies, Inc.

15010 Avenue of Science
Suite 200
San Diego, CA 92128
United States

Full Time Employees87

Key Executives

Dr. Terence E. Winters BSc, Ph.D.582.31kN/A75
Dr. Duane Nash M.D., J.D., M.B.A443.37kN/A46
Mr. Robert A. Ashley M.A.453.53kN/A59
Mr. Michael V. Swanson M.B.AN/AN/A62
Mr. Aron P. Stern M.B.A.N/AN/A63
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vital Therapies, Inc., a biotherapeutic company, focuses on developing a human hepatic cell-based therapy targeting the treatment of acute forms of liver failure in the United States. Its ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patient’s own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is headquartered in San Diego, California.

Corporate Governance

Vital Therapies, Inc.’s ISS Governance QualityScore as of October 15, 2017 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.